科伦博泰生物-B(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06990 科伦博泰生物-B

未开盘 04-16 16:08:12

522.000

+3.000

+0.58%

最高523.500	最低504.000	成交量55.36万
今开516.000	昨收519.000	日振幅3.76%
总市值1,217亿	流通市值849.66亿	总股本2.33亿
成交额2.85亿	换手率0.34%	流通股本1.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科伦博泰生物-B","latestPrice":522,"timestamp":1776326892008,"preClose":519,"halted":0,"volume":553618,"delay":0,"changeRate":0.005780346820809248,"floatShares":162769979,"shares":233185969,"eps":-1.9007315963506617,"marketStatus":"未开盘","change":3,"latestTime":"04-16 16:08:12","open":516,"high":523.5,"low":504,"amount":284994862,"amplitude":0.037572,"askPrice":522,"askSize":3000,"bidPrice":520,"bidSize":800,"shortable":3,"etf":0,"ttmEps":-1.9007315963506617,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776389400000},"marketStatusCode":0,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":519,"openAndCloseTimeList":[[1776303000000,1776312000000],[1776315600000,1776326400000]],"volumeRatio":1.00208,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06990","defaultTab":"news","newsList":[{"id":"1169202362","title":"科伦博泰生物-B2025年研发投入达31亿元，收入稳步增长但亏损扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=1169202362","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169202362?lang=zh_cn&edition=full","pubTime":"2026-04-16 23:10","pubTimestamp":1776352238,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B于报告期内继续聚焦肿瘤领域的生物制药研发，产品管线从Biotech阶段逐步向Biopharma转型。财务数据显示，2025年度公司收入约20.58亿元人民币，较2024年的19.33亿元人民币增长6.46%。总体而言，科伦博泰生物-B在2025年度实现了收入稳步上涨和业务布局的持续深化，同时研发费用的高额投入也带来了亏损的进一步扩大。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627261720","title":"中金：国家优化创新药新药上市首发价格机制 药品行业有望迎高质量发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2627261720","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627261720?lang=zh_cn&edition=full","pubTime":"2026-04-16 14:24","pubTimestamp":1776320685,"startTime":"0","endTime":"0","summary":"中金主要观点如下：优化创新药等新上市药品首发价格机制，实行新上市药品企业自评制度政策鼓励对于新上市药品价格制定，区分高水平创新药、改良新药、通用名药等情形。根据真实世界研究结果和临床使用实效，医药企业可在药品首发价格基础上适当调整价格水平。促进创新药多元支付与价格合理形成，拓宽创新药支付渠道。风险因素研发不及预期，创新药核心产品对外合作进展不及预期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","LU1770034418.SGD","HK0000500386.USD","IE00B5MMRT66.SGD","LU0348784397.USD","HK0000165453.HKD","IE00B543WZ88.USD","HK0000252160.HKD","LU0348766576.USD","01801","LU0455707207.USD","LU2543165471.USD","06160","LU0634319403.HKD","LU1961090484.USD","LU2476274308.USD","06978","09926","LU2097828631.EUR","BK1191","LU0348825331.USD","LU2097828805.USD","LU0196878994.USD","LU2399975544.HKD","LU0348827113.USD","LU1719994722.HKD","LU0417516902.SGD","LU2097828557.USD","LU2488822045.USD","LU0417516738.SGD","BK1161","LU0417516571.SGD","LU1794554557.SGD","LU2097828714.EUR","LU0359202008.SGD","BK1588","LU2778985437.USD","LU1023057109.AUD","06990","LU0348783233.USD","LU0588546209.SGD","LU0561508036.HKD","LU2476274720.SGD","09606","IPOS","LU0502904849.HKD","LU0540923850.HKD","LU2328871848.SGD","01276","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627881282","title":"科伦博泰生物(06990)4月15日认购本金额为1亿元的浙商银行结构性存款II","url":"https://stock-news.laohu8.com/highlight/detail?id=2627881282","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627881282?lang=zh_cn&edition=full","pubTime":"2026-04-15 20:41","pubTimestamp":1776256864,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物(06990)发布公告，于2026年1月19日，本公司订立浙商银行结构性存款协议I，据此，本公司同意认购本金额为人民币2.9亿元的浙商银行结构性存款I。于2026年4月15日，本公司订立浙商银行结构性存款协议II，据此，本公司同意认购本金额为人民币1亿元的浙商银行结构性存款II。于2026年4月15日，本公司订立中国银行结构性存款协议，据此，本公司同意认购本金额为人民币3亿元的中国银行结构性存款。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1231","LU0196878994.USD","BK1560","601916","BK0278","BK1161","02016","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627405121","title":"国办一纸文件定调药价，创新药爆发！涨停名单还在拉长","url":"https://stock-news.laohu8.com/highlight/detail?id=2627405121","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627405121?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:33","pubTimestamp":1776234822,"startTime":"0","endTime":"0","summary":"政策组合拳出击","market":"sh","thumbnail":"https://img3.gelonghui.com/a401d-f3f18d25-b1d2-4d82-b91d-544aa33cb569.jpg?guru_height=718&guru_width=1280&guru_size=112216","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/a401d-f3f18d25-b1d2-4d82-b91d-544aa33cb569.jpg?guru_height=718&guru_width=1280&guru_size=112216"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4422353","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["159992","000919","BK0097","BK0070","BK0077","002038","002589","BK0028","301408","06978","BK0209","BK1583","BK0012","BK0122","000788","BK1574","BK0185","BK0096","BK0132","LU0196878994.USD","BK0102","BK0060","BK1161","BK1587","06990","02162","BK0197","BK0188","600572","600267","600488","BK0239","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101332603","title":"科伦博泰生物公布Sacituzumab Tirumotecan妇科肿瘤研究结果，亮相2026年SGO年会","url":"https://stock-news.laohu8.com/highlight/detail?id=1101332603","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101332603?lang=zh_cn&edition=full","pubTime":"2026-04-14 08:01","pubTimestamp":1776124872,"startTime":"0","endTime":"0","summary":"科伦博泰生物宣布，其SKB264-II-06/MK-2870-002研究的最新数据已在2026年妇科肿瘤学会年会上公布。该研究主要评估了Sacituzumab Tirumotecan在妇科肿瘤领域的应用效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","BK1161","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626818534","title":"摘“B”成功：科伦博泰生物市值破千亿港元，4月14日起简称去掉“B”","url":"https://stock-news.laohu8.com/highlight/detail?id=2626818534","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626818534?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:15","pubTimestamp":1775729700,"startTime":"0","endTime":"0","summary":"4月9日，科伦博泰生物-B（06990）发布公告，宣布香港联合交易所已批准公司不再适用上市规则第18A.09至第18A.11条，自2026年4月14日起，公司中英文简称将不再加上标记“B”，新英文简称为“SKBBIO”，新中文简称为“科伦博泰生物”，公司股份代号仍为“6990”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604093699721844.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0196878994.USD","BK1161","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147694434","title":"科伦博泰生物-B更新2026年3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1147694434","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147694434?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:37","pubTimestamp":1775723855,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B于2026年4月9日发布截至2026年3月31日的股份变动月报。公告显示，报告期内公司未进行新增股份发行、购回或注销，整体股本维持稳定。根据公告，科伦博泰生物-B报告期末已发行普通股总数与上期保持一致。无期权与股权激励计划变动，无任何股份回购或注销活动。截至报告期末，公司股本与公眾持股比例均保持在既定要求范围内。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625944989","title":"科伦博泰生物-B(06990)H股全流通获联交所授出上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2625944989","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625944989?lang=zh_cn&edition=full","pubTime":"2026-04-08 21:06","pubTimestamp":1775653614,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B(06990)发布公告，公司已向联交所申请批准821.43万股H股(相当于根据转换及上市将予转换的公司内资股及非上市外资股总数)上市及准许买卖。董事会欣然宣布，于2026年4月2日，联交所已授出上市批准。基于截至本公告日期的公司股本总数，转换H股占公司股本总数约3.52%，因此，公司H股占公司股本总数的比例将因转换及上市完成而由69.80%增加至73.32%，内资股将由28.21%减少至26.68%，而非上市外资股将由1.99%减少至0.00%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0196878994.USD","BK1161","06990","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622873003","title":"科伦博泰生物-B(06990)：中国证监会就公司H股全流通发出备案通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2622873003","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622873003?lang=zh_cn&edition=full","pubTime":"2026-03-27 23:13","pubTimestamp":1774624388,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B(06990)发布公告，公司已收到中国证监会就实施H股全流通而发出日期为2026年3月26日的备案通知书。根据备案通知书，公司就合计821.4万股内资股及非上市外资股实施H股全流通向中国证监会作出的备案已经完成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06990","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622784848","title":"【券商聚焦】西南证券维持科伦博泰生物-B(06990)“买入”评级 指","url":"https://stock-news.laohu8.com/highlight/detail?id=2622784848","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622784848?lang=zh_cn&edition=full","pubTime":"2026-03-27 14:49","pubTimestamp":1774594198,"startTime":"0","endTime":"0","summary":"金吾财讯 | 西南证券发布研报指，科伦博泰生物-B 2025年收入结构发生积极转变，药品销售收入同比大幅增长949.8%至5.43亿元人民币，占比达26.37%，标志着公司增长动力正从以授权合作收入为主，转向以自有产品商业化销售驱动。2025年为支持产品销售，销售费用同比激增160.1%至4.75亿元人民币，导致调整后年度亏损为2.11亿元，但公司在手现金及金融资产充裕，达45.59亿元。维持对公司的“买入”评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977575","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","600369"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622044491","title":"【券商聚焦】招银国际维持科伦博泰(06990)“买入”评级 指2025年为向商业化转型的关键之年","url":"https://stock-news.laohu8.com/highlight/detail?id=2622044491","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622044491?lang=zh_cn&edition=full","pubTime":"2026-03-25 13:48","pubTimestamp":1774417714,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际研报指，2025年是科伦博泰 向商业化转型的关键之年，公司已从临床阶段的生物科技公司成功转型为拥有4款获批产品的生物制药企业。三大核心资产成功纳入国家医保目录，为2026年的销量增长奠定了坚实基础。该机构预计默沙东有望在2026年提交用于二线及以上子宫内膜癌的上市申请，或有望在2026年底或2027年初获批。维持“买入”评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977202","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621065283","title":"高盛重申“买入”科伦博泰生物-B(06990)：芦康沙妥珠单抗OS数据表现突出 公司增长潜力持续释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2621065283","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621065283?lang=zh_cn&edition=full","pubTime":"2026-03-24 18:30","pubTimestamp":1774348218,"startTime":"0","endTime":"0","summary":"高盛认为，其核心产品芦康沙妥珠单抗已成为公司增长的核心驱动力。2026年，随着产品已纳入国家医保目录，公司预计芦康沙妥珠单抗的销售将实现大幅增长，并有望在已获批适应症中成为医生首选，这部分预计将贡献超过80%的收入。此前，公司已宣布芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阳性非小细胞肺癌的III期研究已达到主要终点，进一步验证这一ADC+IO联用组合的临床价值。RDC的全球热度正在升温，科伦博泰已经提前完成卡位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"高盛重申“买入”科伦博泰生物-B(06990)：芦康沙妥珠单抗OS数据表现突出 公司增长潜力持续释放","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1868836757.USD","BK4533","LU2237443549.SGD","LU2750360641.GBP","LU2750360997.AUD","LU1791807156.HKD","LU1868836591.USD","LU0345770308.USD","LU0345770993.USD","LU2237443382.USD","LU0106831901.USD","LU0251142724.SGD","LU2237443895.HKD","LU2237443978.SGD","LU0742534661.SGD","IE0002270589.USD","LU0096364046.USD","LU2237443465.HKD","BK1161","LU2471134879.HKD","LU1868836914.USD","06990","IE0004091025.USD","BK4552","BK4588","LU2237438978.USD","IE0004086264.USD","LU0251131958.USD","LU1894683348.USD","LU1868837136.USD","IE00BFXG1179.USD","IE00B19Z3B42.SGD","IE0034235188.USD","LU0196878994.USD","GSX","LU2265009873.SGD","BK4585","BK4127","LU2237443622.USD","LU0048573561.USD","IE00B19Z3581.USD","LU1804176565.USD","IE00BSNM7G36.USD","LU1668664300.SGD","BK4516","BK4550","LU2471134796.USD","LU0061475181.USD","LU1894683264.USD","LU2471134523.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621057905","title":"科伦博泰生物-B(06990)： SKB103新药临床试验申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2621057905","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621057905?lang=zh_cn&edition=full","pubTime":"2026-03-24 16:48","pubTimestamp":1774342081,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B 发布公告，本公司自主研发的新型靶向肿瘤相关抗原及免疫肿瘤学抗原的双特异性抗体偶联药物  SKB103的新药临床试验申请已获国家药品监督管理局 药品审评中心批准，用于治疗晚期实体瘤。这是本公司首个进入临床阶段的TAA-PD-L1 bsADC，也是继SKB571之后第二款进入临床阶段的用于肿瘤治疗的bsADC。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"科伦博泰生物-B(06990)： SKB103新药临床试验申请获国家药品监督管理局批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU0196878994.USD","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125512630","title":"科伦博泰生物-B SKB103新药临床试验申请获中国国家药监局批准用于晚期实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1125512630","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125512630?lang=zh_cn&edition=full","pubTime":"2026-03-24 16:47","pubTimestamp":1774342031,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B宣布，其创新药物SKB103的新药临床试验申请已正式获得中国国家药品监督管理局批准，将针对晚期实体瘤开展临床研究。此次获批标志着该药物在肿瘤治疗领域迈出关键一步，为后续研发奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","BK1161","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621059310","title":"港股异动 | TSLP抗体疗法I期临床研究结果发表 科伦博泰生物-B(06990)涨超7% 和铂医药-B(02142)涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621059310","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621059310?lang=zh_cn&edition=full","pubTime":"2026-03-24 15:02","pubTimestamp":1774335720,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物-B、和铂医药-B午后涨幅扩大。截至发稿，科伦博泰生物涨7.34%，报426.8港元；和铂医药涨4.65%，报11.7港元。消息面上，3月23日，和铂医药宣布，HBM9378首次人体1期临床试验结果已在线发表于同行评议期刊Drug Design, Development and Therapy。公开资料显示，HBM9378由和铂医药与科伦博泰联合开发，双方共同享有其全球权益。2025年1月，和铂医药及科伦博泰与Windward Bio签订战略合作，授予后者在全球范围内对该抗体进行研究、开发、生产和商业化的独家权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0196878994.USD","06990","BK4588","02142","BK1583","BK4585","VXUS","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621037914","title":"大行评级丨高盛：下调科伦博泰生物-B目标价至526.49港元，下调盈测","url":"https://stock-news.laohu8.com/highlight/detail?id=2621037914","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621037914?lang=zh_cn&edition=full","pubTime":"2026-03-24 11:37","pubTimestamp":1774323421,"startTime":"0","endTime":"0","summary":"高盛发表研报指，科伦博泰生物-B去年下半年收入为11亿元，高于该行及市场预期，主要由授权收入按年增长79%带动；产品销售按半年跌25%，则逊预期，主要由于核心产品sac-TMT在2025年主要以自费形式销售，患者可及性受限，以及纳入国家医保目录后价格调整的渠道返点影响。\r\n\r\n　　管理层预期今年sac-TMT销售将倍增，目标成为医保目录内各个适应症的首选药物，占销售逾80%。该行将2026及2027年的每股盈利预测，由3.43及8.81元，下调至1.39及7.32元，以反映去年下半年业绩表现，及近期药物销售预测下调等；目标价由531.69港元降至526.49港元，维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260324/32093341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621032469","title":"大行评级丨瑞银：下调科伦博泰生物-B目标价至578港元，重申“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2621032469","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621032469?lang=zh_cn&edition=full","pubTime":"2026-03-24 11:07","pubTimestamp":1774321622,"startTime":"0","endTime":"0","summary":"瑞银发表研报指，科伦博泰生物-B去年下半年收入11亿元，按年升101%，符合该行及市场预期；净亏损2.37亿元，好过该行及市场预期；毛利率达74%，较2024年的66%及2025上半年的69%有所提升，主要受产品销售占比提升带动。因应该业绩，该行将2026及2027年sac-TMT销售预测下调至14亿元及26亿元，但上调授权收入预测，因今年更多第三期临床数据释出后或有潜在的里程碑付款；重申“买入”评级，目标价由593港元下调至578港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260324/32093225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188074054","title":"科伦博泰生物-B公布2025年度业绩：多款产品成功上市，梯队化管线蓄势待发","url":"https://stock-news.laohu8.com/highlight/detail?id=1188074054","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188074054?lang=zh_cn&edition=full","pubTime":"2026-03-24 10:32","pubTimestamp":1774319536,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B（股票代码：06990）正式披露了其2025年度的财务与业务进展。报告期内，公司成功实现了多款创新产品的商业化上市，标志着其研发成果进入收获期。与此同时，公司构建的梯队化产品管线布局完善，后续增长动力充足，展现出强劲的发展潜力，为未来的持续飞跃奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","BK1161","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172232004","title":"异动解读 | 瑞银重申“买入”评级，科伦博泰生物-B盘中大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=1172232004","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172232004?lang=zh_cn&edition=full","pubTime":"2026-03-24 10:26","pubTimestamp":1774319198,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B今日盘中大涨5.03%，引起了市场的广泛关注。消息面上，瑞银发表研究报告指出，科伦博泰生物-B去年下半年收入同比增长101%，符合预期；净亏损好于预期；毛利率提升至74%。尽管瑞银下调了其目标价及部分盈利预测，但报告重申了“买入”评级，这增强了市场对公司基本面的信心。报告显示，公司毛利率的提升主要受产品销售占比提高带动。瑞银预计，随着今年更多第三期临床数据释出，公司可能获得潜在的里程碑付款，从而带来授权收入。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621721247","title":"ADC一哥，扣动新一轮增长扳机","url":"https://stock-news.laohu8.com/highlight/detail?id=2621721247","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621721247?lang=zh_cn&edition=full","pubTime":"2026-03-23 18:22","pubTimestamp":1774261341,"startTime":"0","endTime":"0","summary":"结合其成熟的“端到端”药物开发能力及经过市场验证的商业化路径，公司已悄然扣动新一轮的增长扳机。过去一年多来，芦康沙妥珠单抗获批了4项适应症，一举囊括了肺癌、乳腺癌两大癌种。比如，在备受瞩目的RDC领域，科伦博泰的SKB107在去年7月启动了一项治疗晚期实体瘤骨转移患者的I期临床。在ADC领域完成体系化的跨周期布局之后，科伦博泰正依托底层的创新势能，稳步向综合型、全面型治疗领域延伸。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","BK4080","LU0196878994.USD","BK4231","ADC","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":0.0657},{"period":"1month","weight":0.2482},{"period":"3month","weight":0.1033},{"period":"6month","weight":0.1322},{"period":"1year","weight":0.6731},{"period":"ytd","weight":0.3233}],"compareEarnings":[{"period":"1week","weight":0.0249},{"period":"1month","weight":0.0203},{"period":"3month","weight":-0.0168},{"period":"6month","weight":0.0454},{"period":"1year","weight":0.2535},{"period":"ytd","weight":0.0298}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四川科伦博泰生物医药股份有限公司是一家主要从事新药业务的研发、生产和销售的中国公司。该公司主要从事肿瘤学、免疫学及其他治疗领域的创新药物的研发、制造及商业化。该公司的产品为抗体药物偶联物（ADC）SKB264及A166。该公司产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等非肿瘤疾病的治疗。","exchange":"SEHK","name":"科伦博泰生物-B","nameEN":"SKB BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦博泰生物-B(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦博泰生物-B(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦博泰生物-B,06990,科伦博泰生物-B股票,科伦博泰生物-B股票老虎,科伦博泰生物-B股票老虎国际,科伦博泰生物-B行情,科伦博泰生物-B股票行情,科伦博泰生物-B股价,科伦博泰生物-B股市,科伦博泰生物-B股票价格,科伦博泰生物-B股票交易,科伦博泰生物-B股票购买,科伦博泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦博泰生物-B(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦博泰生物-B(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}